Download presentation
Presentation is loading. Please wait.
Published byAbel Lane Modified over 9 years ago
1
報告者: fellow 1 陳筱惠 指導醫師:陳冠興醫師 Commented by CV1 張其任醫師
2
Name: 張 O 嗣 Sex: female Age: 90-year-old Chart number: 487733 Date of admission: 2011/11/18
3
Persistent dizziness for 1 day
4
Underlying diseases: chronic kidney disease (stage 4), congestive heart failure, and atrial fibrillation Dizziness with bradycardia episode at home (HR around 40bpm) Associated S/S: no palpitation, chest pain, cold sweating, or consciousness disturbance At ER: clear consiousness, af SVR
5
Hypertension (BP when OPD follow-up: 180~/70~mmHg) Heart failure, LVEF:68%, HCVD related, atrial fibrillation rhythm Chronic kidney disease, stage 4, eGFR: 29.4ml/min, 2011/04/24 crea: 1.64mg/dl Obstrutive sleep apnea syndrome with restrictive lung Asthma history Other significant systemic diseases: denied
6
Doxazosin 4mg 1# bid Isosorbide-5-mononitrate cr 60mg 1# qd Furosemide 40ng 0.5# qd Aliskiren 150mg 1# qd 2011/06/28~ Exforge (Amlodipine 5mg + Valsartan 80mg) 1# bid 2011/11/15~ ◦ Micardis Plus (Telmisartan 40mg + HCTZ 12.5mg) 1# qd 2011/10/18~2011/11/15 ◦ Telmisartan 40mg
7
Allergy: no known allergy Alcohol: denied; betel-nut: denied; cigarette: denied Over-the-counter medication or chinese herb: nil
8
No family history of malignancy, bleeding diathesis, heart, liver, kidney, or hereditary diseases
9
Vital signs: blood pressure: 135/58mmHg; temperature: 36.5‘C; pulse rate: 44/min; respiratory rate: 18/min General appearance: acute ill looking Eye: conjunctiva: pale, sclera: no icteric Neck: supple, no lymphadenopathy or jugular vein engorgement Chest: symmetric expansion breathing sound: bilateral clear heart sound: irregular heart beats, no S3 or S4, no murmurs Abdomen: soft, flat, no tenderness, muscle guarding, or rebounding liver/spleen: impalpable bowel sound: normoactive Extremities: no lower limb pitting edema Skin: intact, no rash
10
WBC6.2x1000/ul Hgb8.3 g/dl Hct25.4 % MCV87 fL PLT159 x1000/uL Segment78.9 % BUN118.1 mg/dL Creatinine4.43 mg/dl GPT9 IU/L Na134 mEq/L K8.2 mEq/L Ca8.2 mg/dL Mg2.3 mEq/L Tropo - I<0.01 ng/mL
11
Atrial fibrillation with slow ventricular rate, suspect hyperkalemia induced Acute on chronic kidney disease, favor ARB drug effect, complicated with hyperkalemia and azotemia Hypertension, poorly controlled Heart failure, LVEF:68%, HCVD related, atrial fibrillation rhythm Obstrutive sleep apnea syndrome with restrictive lung Asthma history
12
H/D U/O2020660740860 BW55.4654.855.956.6 BUN118.158.8 Crea4.432.65 Na134138 K8.55.1 Ca P C0221.3 189/88 mmHg 141/72 mmHg 149/70 mmHg 165/79 mmHg
13
U/O23016302450350920 BW69.559.158.3 BUN68.773 Crea2.822.45 Na125123 K4.75.0 Ca8.38.0 P4.84.5 C02 190/99 mmHg 159/72 mmHg 186/84 mmHg 206/94 mmHg 186/89 mmHg Kidney echo
14
U/O900820400810710 BW57.957.259.560.7 BUN5151.4 Crea1.872.63 Na127123 K4.54.2 Ca8.27.7 P2.73.0 C02 201/96 mmHg 181/80 mmHg 145/66 mmHg 179/86 mmHg 156/72 mmHg Cortisol 14.1 Renin 1644 Aldosterone 328 TSH 0.77 Free T4 26.939
15
U/O4001210700300400 BW61.661.161.362.4 BUN58.763.372.8 Crea2.592.313.12 Na123125126 K4.95.35.6 Ca8.0 P4.75.5 C0215.417.3 194/87 mmHg 172/79 mmHg 172/69 mmHg 151/70 mmHg 209/86 mmHg
16
U/O13202500600300950 BW61.66062 63.1 BUN80.4 Crea2.65 Na128 K4.8 Ca8.2 P6.0 C0221.1 179/82 mmHg 156/76 mmHg 174/84 mmHg 169/82 mmHg 176/75 mmHg Renin 995
17
U/O21801400650200600 BW61.8 BUN80.747 Crea3.012.08 Na123130 K3.93.8 Ca7.98.7 P5.12.7 C02 188/84 mmHg 193/85 mmHg 192/78 mmHg 201/95 mmHg 210/85 mmHg H/D
18
U/O45070030013090 BW58.2 BUN58.1 Crea3.12 Na127 K4.1 Ca8.4 P4.3 C0222.5 203/90 mmHg 191/83 mmHg 204/90 mmHg 174/75 mmHg 172/95 mmHg
19
U/O100801502300 BW58.7 BUN47.3 Crea4.78 Na127 K4.9 Ca7.9 P3.6 C0224.9 177/81 mmHg 178/96 mmHg 196/89 mmHg 179/88 mmHg 202/89 mmHg Hickman implantation
20
U/O0750650500600 BW54.9 BUN37.5 Crea4.83 Na134 K4.3 Ca8.0 P4.6 C0223.7 168/74 mmHg 164/87 mmHg 163/69 mmHg 141/74 mmHg 168/76 mmHg Renal angiography
21
U/O1100 22501300950 BW BUN37.944.5 Crea4.924.57 Na131 K4.44.5 Ca7.88.5 P4.95.4 C0223.422.6 197/85 mmHg 151/69 mmHg 168/79 mmHg 122/61 mmHg 161/74 mmHg Hold H/D
22
U/O14501400 BW50.2 BUN36.519.6 Crea2.831.74 Na133136 K4.45.0 Ca9.08.6 P4.24.0 C02 147/81 mmHg 134/64 mmHg 119/54 mmHg 1/17 remove hickman
23
Renal Artery Stenosis: Optimizing Diagnosis and Treatment Progress in Cardiovascular Diseases 54 (2011) 29–35
24
1 st : atherosclerotic lesions, 90% of all renovascular lesions ◦ Typically in older individuals ◦ An equal prevalence in men and women ◦ Predominantly at or near the origin of the renal artery and usually are associated with aortic disease ◦ May present with hypertension or renal insufficiency
25
2 nd : fibromuscular dysplasia (FMD) ◦ More often in young women ◦ Usually associated with hypertension without renal insufficiency
26
A limited literature addresses the clinical factors that are predictive of finding atherosclerotic RAS and that may be useful in guiding appropriate screening.
28
Doppler ultrasound Computed tomography angiography (CTA) and magnetic resonance angiography (MRA) Conventional angiography Imaging For Renovascular Disease Seminars in Nephrology, Vol 31, No 3, May 2011, pp 272-282
29
Duplex ultrasonography: screening test ◦ Sensitivity: 92.5% to 98%; specificity: 96% to 98% ◦ Nontoxic ◦ No exposure to ionizing radiation ◦ Capable and reliable ◦ Major limitation: dependence on technician skill for acquisition of adequate images; others: obesity, bowel gas, and recent food intake
32
Computed tomography angiography (CTA): ◦ Sensitivity and specificity: > 95% ◦ Multicenter Renal Artery Diagnostic Imaging Study in Hypertension (RADISH) study SEN 64%, SPE 93% ◦ Qualitative ◦ Risk of contrast nephropathy
33
Magnetic resonance angiography (MRA): ◦ Slightly lower sensitivities and specificities than CTA; RADISH study SEN 62%, SPE 84% ◦ To measure flow, renal perfusion, and renal function ◦ Poorer spatial resolution, limited availability, patient tolerance, and the need for extended breath- holding ◦ Nephrogenic sclerosing fibrosis associated with Gadolinium in patients with renal insufficiency
34
Duplex ultrasonography is inferior to MRA and CTA. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med 2001;135:401-411.
35
Captopril renography: ◦ Poor screening test Dependent on comparative imaging of the right and left kidneys The incidence of bilateral RAS is approximately 30%. ◦ May be useful when trying to determine the physiologic significance of a known intermediate stenosis
36
Invasive angiography: gold standard ◦ Confirm the diagnosis based on prior noninvasive testing and with the intent to perform an intervention ◦ The most commonly used methodology: intra- arterial digital subtraction angiography ◦ Complications: related to the vascular access, placement of the guidecatheter into the renal artery, balloon and stent deployment, and contrast administration
37
◦ Carbon dioxide (CO2) Image quality is reduced. May create greater uncertainty about lesion severity unless combined with judicious use of iodinated contrast
38
Medical therapy Revascularization: balloon angioplasty +- stenting or Surgical bypass or reconstruction Goals: ◦ Blood pressure control ◦ Treatment of heart failure and/or pulmonary edema ◦ Prevention of nephropathy
39
Medical therapy Lifestyle interventions: ◦ Dietary recommendations in atherosclerotic RAS: Increased intake of fruits and vegetables, dietary calcium through low fat dairy products
40
Angiotensin-converting enzyme (ACE) inhibitors ◦ Potential to induce acute hemodynamically mediated renal failure in patients with RAS ◦ Lower cardiovascular event rates (10% vs 13%) and need for dialysis (1.5% vs 2.5%) ◦ The cost of an increased risk of hospitalization for acute renal failure (1.2 vs 0.6%) Selection bias: patients with better renal function and/or less severe disease are treated with these agents resulting in an apparent improvement of outcome
41
Other agents used to control the atherosclerotic process are important for the care of patients with atherosclerotic RAS. ◦ Statins: decrease death, limit lesion progression, and promote restenosis-free survival ◦ Platelet inhibitors: prevention of future cardiovascular events
42
Revascularization: ◦ Balloon angioplasty +- stenting: Lesion severity, renal function, the skill level of the operators, and complication rates ◦ Surgical bypass or reconstruction: Not benefit over angioplasty High rates of adverse outcomes with surgery, including perioperative mortality of approximately 10%
43
When stenting is performed, there are a number of technical factors that should be considered as part of the procedure. ◦ “No touch” technique for engaging a catheter into the renal artery reduce the risk of atheroembolism ◦ No embolic protection device is approved by the Food and Drug Administration for use in the renal artery. ◦ Abciximab (a platelet glycoprotein IIbIIIa inhibitor) ??
44
A “cure” of hypertension with revascularization ◦ < 10% in patients with atherosclerotic RAS ◦ Approximately 50% in patients with FMD Younger patients more likely to achieve this outcome. Consistent and sustained blood pressure– lowering effect of revascularization
45
Considerable controversy exists regarding the use of revascularization of atherosclerotic RAS to treat or prevent the development of ischemic nephropathy. ◦ Stent revascularization in patients with ischemic nephropathy and significant stenoses resulted in a slower rate of progression of nephropathy. ◦ In a minority of patients, an actual improvement in renal function is seen with either stenting or surgical revascularization.
46
FMD: balloon angioplasty ◦ In a minority of FMD cases, there will be concomitant aneurysms of the renal artery. Atherosclerotic RAS ◦ Stenting has proven superior to balloon angioplasty.
49
Left kidney: 9.9 cm Right kidney: 7.7 cm
50
Right renal artery: occluded Left renal artery: proximal 71% stenosis ◦ Balloon dilatation procedures: 56% residual stenosis ◦ Stenting: 5% residual stenosis
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.